The sample included 300 participants recruited from an online panel. Participants were included if they had received a cancer diagnosis from a clinician and reported receiving anti-cancer treatment. We conducted five linking procedures and selected an optimal one to generate the crosswalk table between the two measures.
The linked T scores of all five methods showed acceptably small mean differences from the observed T scores, and the standard deviation (SD), and root-mean-squared deviation (RMSD) of the differences were generally similar across all methods. After comparing across all statistics, the Stocking-Lord approach was considered as the optimal approach to compute the crosswalk table for converting SARC-F raw scores to PROMIS PF 8c scores. The crosswalk table shows that the SARC-F cut-off value of 4 between healthy versus symptomatic with a corresponding score of 37 fell in the range of moderate physical function limitation from 30 to 39 on the PROMI PF 8c T score metric.
The linkage in this study has potential for improving clinical and research activities for people with cancer and perhaps others with a similar range of physical function. It facilitates the interpretability in scores of both measures on a common metric anchored on general population for further group-level analysis. Researchers can use this crosswalk to harmonize data collected from either instrument without requiring all cohorts to administer the same instrument for a prospective data collection or retrospective data analysis purpose or for a cross-study effectiveness study.
方法:样本包括从在线小组招募的300名参与者。如果参与者接受了临床医生的癌症诊断并报告接受了抗癌治疗,则将其包括在内。我们进行了五个链接程序,并选择了一个最佳程序来生成两个度量之间的人行横道表。
结果:所有五种方法的相关T评分均显示出与观察到的T评分有可接受的小均值差异,和标准偏差(SD),在所有方法中,差异的均方根偏差(RMSD)通常相似。在比较所有统计数据后,Stocking-Lord方法被认为是计算将SARC-F原始分数转换为PROMISPF8c分数的人行横道表的最佳方法。人行横道表显示,健康与症状之间的SARC-F临界值为4,相应得分为37,在PROMIPF8cT评分指标上,处于中度身体功能限制的范围,从30到39。
结论:这项研究中的联系有可能改善癌症患者的临床和研究活动,可能还有其他身体功能相似的人。它有助于在基于一般人群的共同度量标准上对两种度量的得分进行解释性,以进行进一步的群体级分析。研究人员可以使用此人行横道来协调从任一仪器收集的数据,而无需所有队列管理同一仪器以进行前瞻性数据收集或回顾性数据分析目的或进行跨研究有效性研究。